Your session is about to expire
← Back to Search
BGB 324 (after surgery) for Brain Tumor
Study Summary
This trial is testing an AXL inhibitor to see if it can stop the growth of glioblastoma cells.
- Brain Tumor
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You cannot participate if you are currently taking any other experimental drugs.You have had allergic reactions to similar substances as BGB324 in the past. You can refer to the investigator brochure for more details.You cannot participate if you have a history of a bleeding disorder.You have severe heart failure that causes symptoms even with mild physical activity.You are currently taking a medication that can cause a certain type of heart rhythm problem called torsade de pointes. You will need to stop taking this medication at least two weeks before starting the study treatment.You have a family member or personal history of heart problems that can cause irregular heartbeats.
- Group 1: AXL inhibitor BGB324 then surgery
- Group 2: Surgery then AXL inhibitor BGB324
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any open enrolment opportunities for this clinical trial?
"As indicated on clinicaltrials.gov, this medical trial is not currently enrolling patients; it was initially published on the 2nd of January 2020 and last edited in December 1st 2022. However, there are still 547 active trials recruiting participants at present."
What is the number of enrollees currently involved in this research?
"Unfortunately, this medical study is not currently accepting participants. Initially posted on February 1st 2020 and last updated December first 2022, if you are looking for alternatives there are 543 trials recruiting patients with central nervous system neoplasms and 4 studies actively enrolling those who have gone through surgery to receive BGB 324."
Does the age criterion for this exploration extend to octogenarians?
"As per the specifications of this clinical trial, individuals aged 18 and above but below 120 years old are eligible to take part."
How many healthcare facilities are presently executing this trial?
"Currently, 8 sites are conducting this clinical trial; some of these include New york, Detroit and Baltimore. To reduce travel demands for patients enrolled in the study, it would be beneficial to choose a location nearest you."
Has this type of clinical trial been conducted before?
"Since 2016, BGB 324 (after surgery) has been studied in numerous clinical trials. The initial trial was backed by BerGenBio ASA and had 23 participants; it eventually led to the drug being approved for Phase 1 use. Currently, there are 4 ongoing studies on the medication across 9 cities distributed over 3 countries."
Is enrollment still open for the clinical trial?
"This trial is open to 20 individuals over 18 years old suffering from central nervous system neoplasms. Applicants must have experienced no more than two previous recurrences, and be 12 weeks removed from radiation therapy, 4 weeks away from investigational agents not sanctioned by the FDA, as well as certain antiangiogenesis drugs (bevacizumab, aflibercept, ramucirumab etc.), and 3 weeks distant from non-nitrosourea chemotherapy."
Share this study with friends
Copy Link
Messenger